Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820652 | 0.86 | PPARD (0.58) | PPARDPPARGTARBP2PPARAKDM4E | |
| SCHEMBL6606824 | 0.84 | SMN1; SMN2 (0.59) | PPARDPPARGTARBP2PPARAKDM4E | |
| SCHEMBL13115925 | 0.83 | PPARG (0.46) | PPARDPPARGPPARAKDM4EMEN1 | |
| SCHEMBL18004129 | 0.81 | TARBP2 (0.70) | PPARDPPARGTARBP2PPARAKDM4E | |
| SCHEMBL13116025 | 0.80 | POLB (0.44) | PPARDPPARGPPARAKDM4EMEN1 | |
| SCHEMBL4478993 | 0.78 | PPARG (0.44) | PPARDPPARGPPARAKDM4EPTPN1 | |
| SCHEMBL3968786 | 0.77 | NOTUM (0.42) | PPARDPPARGPPARAKDM4EPTPN1 | |
| SCHEMBL4906335 | 0.77 | HSD17B10 (0.55) | PPARDPPARGTARBP2PPARAKDM4E | |
| SCHEMBL6606155 | 0.77 | PPARA (0.52) | PPARDPPARGPPARAKDM4EMAPT | |
| SCHEMBL6602492 | 0.77 | SMN1; SMN2 (0.59) | PPARDPPARGTARBP2PPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | PPARD 2/4885PPARG 3/4885TARBP2 4039/4885 |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885TARBP2 3484/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885TARBP2 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.